High nuclear expression levels of histone-modifying enzymes LSD1, HDAC2 and SIRT1 in tumor cells correlate with decreased survival and increased relapse in breast cancer patients

Table 1 Clinicopathological data of the 460 breast cancer patients used in the study

Characteristic	Mean (range)	N = 460	%
Follow-up (years)	11.8 (0.16-27.55)
Age (years)	58.3 (23–89)
<45		90	20
45-55		106	23
55-65		107	23
≥65		157	34
Tumor size (T)
1		182	40
2		227	49
3-4		51	11
Nodal status (N)
Negative		236	51
Positive		224	49
ER
Positive		204	44
Negative		256	56
PgR
Positive		223	49
Negative		237	51
HER2
No overexpression		413	90
Overexpression		47	10
Histologic type
Ductal		418	91
Other		42	9
Tumor grade
1		71	16
2		222	48
3		167	36
Local treatment
Mastectomy without RT		180	39
Mastectomy with RT		97	21
BCS with RT		183	40
Systemic treatment
Chemotherapy alone		89	19
Endocrine therapy alone		77	17
Chemo- and endocrine therapy		18	4
None		276	60

Clinicopathological characteristics of the cohort of breast cancer patients. Statistical analyses were performed with all patients (n = 460) with complete clinicopathological data and nuclear staining data for LSD1, HDAC2 and SIRT1. Tumor size (T) and nodal status (N) were based on the TNM staging criteria. ER: estrogen receptor, PgR: progesterone receptor, HER2: human epidermal growth factor receptor 2, RT: radiotherapy, BCS: breast conserving surgery.

ISSN: 1471-2407